No increased heart failure with newer diabetes drugs

Gliptins and glitazones do not appear to increase heart failure rates in diabetes patients and in fact they reduce them, a large UK study has found.

The study of nearly half a million patients in primary care found that over an eight-year follow-up, those prescribed a gliptin as part of dual therapy had 14% lower odds of heart failure, compared with non-users.

Use of a glitazone cut risk of heart failure by an even